Abbott Laboratories: Mixed Q1 Results, Lowered EPS Guidance
Abbott Laboratories (ABT) reported mixed first-quarter results, cut its 2026 adjusted EPS guidance tied to the Exact Sciences acquisition, and faced a large baby formula legal verdict. The stock is down 15.9% over 30 days.
Key Numbers
Abbott Laboratories (ABT) reported mixed first-quarter results for 2026, cutting its full-year adjusted EPS guidance in connection with the Exact Sciences acquisition, while a large baby formula legal verdict raised new questions. The stock has fallen 15.9% over 30 days.
Key Financial Results
| Metric | Q1 2026 | YoY Change |
|---|---|---|
| Revenue | Not disclosed | - |
| Net Income | Not disclosed | - |
| Adjusted EPS | Expected decline | - |
Note: Exact figures for Q1 were not provided in the source.
Highlights from the Report
- Q1 results were mixed, with weakness in some segments.
- The company lowered its 2026 adjusted EPS guidance due to the Exact Sciences acquisition.
- A large baby formula legal verdict raised concerns about potential liabilities.
Future Guidance
Abbott lowered its 2026 adjusted EPS guidance, but specific numbers were not disclosed.
Impact on Stock
ABT shares fell 15.9% over 30 days, reflecting a sharp reset in market expectations following the negative news.
What This Means for Investors
Abbott Laboratories faces multiple headwinds including weak Q1 performance, guidance cuts from the Exact Sciences deal, and legal risks from the baby formula case. Investors should monitor legal and financial developments closely.
Frequently Asked Questions
Found this useful? Share it